Search research articles
Contact Us
Filters
Showing results (471-480 of 616) with videos related to
Page
of 62
Sort By:
Cardiovascular Endocrinology & Metabolism
|
June 29, 2026
Proteomics analysis of empagliflozin in patients without diabetes or overt heart failure from empagliflozin and cardiac remodeling in people without diabetes CardioLink-7 randomized clinical trial
Wei-Siang Chen, Ning-I Yang, Subodh Verma, et al.
American Journal of Physiology. Endocrinology and Metabolism
|
July 17, 2008
Adiponectin deficiency promotes endothelial activation and profoundly exacerbates sepsis-related mortality
Hwee Teoh, Adrian Quan, K W Annie Bang, et al.
Journal of the American College of Cardiology
|
June 24, 2024
Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials
Subodh Verma, Javed Butler, Barry A Borlaug, et al.
Journal of Clinical Lipidology
|
December 29, 2023
Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3
Andre Zimerman, Stephen D Wiviott, Jeong-Gun Park, et al.
JAMA Cardiology
|
May 24, 2023
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial
Javed Butler, Muhammad Shariq Usman, Gerasimos Filippatos, et al.
European Journal of Preventive Cardiology
|
March 14, 2024
Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial
Andre Zimerman, Stephen D Wiviott, Jeong-Gun Park, et al.
European Heart Journal
|
May 13, 2024
Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials
Sanjiv J Shah, Kavita Sharma, Barry A Borlaug, et al.
European Heart Journal
|
October 10, 2024
Great debate: pre-diabetes is not an evidence-based treatment target for cardiovascular risk reduction
Nikolaus Marx, Lars Rydén, Massimo Federici, et al.
Journal of the American College of Cardiology
|
September 1, 2024
Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program
Subodh Verma, Mark C Petrie, Barry A Borlaug, et al.
JACC. Heart Failure
|
May 7, 2025
Rationale and Design of the Dapagliflozin Effect on Cardiovascular Events in Acute Heart Failure (DAPA ACT HF)-TIMI 68 Trial
David D Berg, Siddharth M Patel, Paul M Haller, et al.
Page
of 62
Search research articles
Search
Showing results (471-480 of 616) with videos related to
Sort By:
Page
of 62
Cardiovascular Endocrinology & Metabolism
|
June 29, 2026
Proteomics analysis of empagliflozin in patients without diabetes or overt heart failure from empagliflozin and cardiac remodeling in people without diabetes CardioLink-7 randomized clinical trial
Wei-Siang Chen, Ning-I Yang, Subodh Verma, et al.
American Journal of Physiology. Endocrinology and Metabolism
|
July 17, 2008
Adiponectin deficiency promotes endothelial activation and profoundly exacerbates sepsis-related mortality
Hwee Teoh, Adrian Quan, K W Annie Bang, et al.
Journal of the American College of Cardiology
|
June 24, 2024
Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials
Subodh Verma, Javed Butler, Barry A Borlaug, et al.
Journal of Clinical Lipidology
|
December 29, 2023
Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3
Andre Zimerman, Stephen D Wiviott, Jeong-Gun Park, et al.
JAMA Cardiology
|
May 24, 2023
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial
Javed Butler, Muhammad Shariq Usman, Gerasimos Filippatos, et al.
European Journal of Preventive Cardiology
|
March 14, 2024
Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial
Andre Zimerman, Stephen D Wiviott, Jeong-Gun Park, et al.
European Heart Journal
|
May 13, 2024
Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials
Sanjiv J Shah, Kavita Sharma, Barry A Borlaug, et al.
European Heart Journal
|
October 10, 2024
Great debate: pre-diabetes is not an evidence-based treatment target for cardiovascular risk reduction
Nikolaus Marx, Lars Rydén, Massimo Federici, et al.
Journal of the American College of Cardiology
|
September 1, 2024
Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program
Subodh Verma, Mark C Petrie, Barry A Borlaug, et al.
JACC. Heart Failure
|
May 7, 2025
Rationale and Design of the Dapagliflozin Effect on Cardiovascular Events in Acute Heart Failure (DAPA ACT HF)-TIMI 68 Trial
David D Berg, Siddharth M Patel, Paul M Haller, et al.
Page
of 62